Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Interventional × AML × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2/3 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1820 Carcinoma, Non-Small-Cell Lung 1096 Breast Neoplasms 1093 Leukemia, Myeloid, Acute 863 Neoplasm Metastasis 796 Melanoma 696 Lymphoma 659 Colorectal Neoplasms 654 Multiple Myeloma 650 Ovarian Neoplasms 610 Pancreatic Neoplasms 596 Lymphoma, Non-Hodgkin 588 Prostatic Neoplasms 587 Recurrence 576 Precursor Cell Lymphoblastic Leukemia-Lymphoma 519 Lung Neoplasms 501 Leukemia, Lymphocytic, Chronic, B-Cell 494 Glioblastoma 478 Leukemia 445 Lymphoma, Large B-Cell, Diffuse 389 Brain Neoplasms 382 Lymphoma, Follicular 371 Stomach Neoplasms 346 Carcinoma, Renal Cell 346 Squamous Cell Carcinoma of Head and Neck 337 Myelodysplastic Syndromes 337 Carcinoma, Hepatocellular 330 Advanced Solid Tumors 320 Glioma 312 Lymphoma, Mantle-Cell 309

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06731699 2024-12-17

A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS

Chengdu FenDi Pharmaceutical Co., Ltd.

Phase 1 Recruiting

AML

Data powered by HemOnc (CC BY 4.0) Colophon ⚡